Related references
Note: Only part of the references are listed.ABCG2: A perspective
Robert W. Robey et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
Jenni E. Keskitalo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simastatin
Jenni E. Keskitalo et al.
PHARMACOGENOMICS (2009)
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin
Satoshi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent:: the contribution of transporting activity changes by SLCO1B1*15
Jian Wei Deng et al.
PHARMACOGENETICS AND GENOMICS (2008)
Global analysis of genetic variation in SLCOIB1
Marja K. Pasanen et al.
PHARMACOGENOMICS (2008)
Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans
J. H. Choi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers
I. Ieiri et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
Richard H. Ho et al.
PHARMACOGENETICS AND GENOMICS (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart
Markus Grube et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
Mikko Niemi et al.
PHARMACOGENETICS AND GENOMICS (2006)
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
Mikko Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effects of organic anion transporting polypeptide IBI haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
Kazuya Maeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Impact of the SLCOIBI polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
Michael Igel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells
K Kopplow et al.
MOLECULAR PHARMACOLOGY (2005)
Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase
H Fujino et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2005)
Effect of OATPIBI (SLCOIBI) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
JY Chung et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
Y Kameyama et al.
PHARMACOGENETICS AND GENOMICS (2005)
Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1
CP Chen et al.
DRUG METABOLISM AND DISPOSITION (2005)
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
M Niemi et al.
PHARMACOGENETICS (2004)
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
J Mwinyi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane
D Kobayashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics
Y Nishizato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Polymorphisms in OATP-C -: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
RG Tirona et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
